COVID-19 Vaccine Split-Dosing Proves Safe, Noninferior to Conventional Dosing
How does split dosing of COVID-19 vaccines compare with conventional dosing with respect to antibody responsiveness and safety?
How does split dosing of COVID-19 vaccines compare with conventional dosing with respect to antibody responsiveness and safety?
In patients using as-needed short-acting beta2-agonists, how are exacerbations associated with asthma control, maintenance adherence, and disease severity?
A real-world study assessed how pediatric patients with moderate to severe asthma responded to the use dupilumab, mepolizumab, and omalizumab.
How rapid is the onset of effective action when using azelastine HCl 0.15% to relieve nasal symptoms of seasonal allergic rhinitis?
While mepolizumab has proven safe and effective for severe asthma, how has it performed in treating those with allergic vs non-allergic asthma?
Researchers assessed the link between smell loss in CRSwNP and other disease attributes, as well as the effect of dupilumab according to smell loss severity.
What are the most significant predictors of airflow limitation in children 5 to 18 years of age with severe asthma?
Which clinical screening markers predict aspirin-exacerbated respiratory disease in patients with chronic rhinosinusitis with nasal polyps?
How does having atopic dermatitis at 2 years of age affect the risk of developing allergic respiratory disease by 10 years of age?
The phase 3 EPITOPE trial assessed the safety and efficacy of epicutaneous immunotherapy for peanut allergy in children under 4 years old.